[1]
|
Kazandjian, D. (2016) Multiple Myeloma Epidemiology and Survival: A Unique Malignancy. Seminars in Oncology, 43, 676-681. https://doi.org/10.1053/j.seminoncol.2016.11.004
|
[2]
|
Kumar, S.K., Rajkumar, V., Kyle, R.A., et al. (2017) Multiple Myeloma. Nature Reviews Disease Primers, 3, Article No. 17046. https://doi.org/10.1038/nrdp.2017.46
|
[3]
|
Rajkumar, S.V., Dimopoulos, M.A., Palumbo, A., et al. (2014) International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. The Lancet Oncology, 15, e538-e548. https://doi.org/10.1016/S1470-2045(14)70442-5
|
[4]
|
Lazaris, V., Hatziri, A., Symeonidis, A., et al. (2021) The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges. Frontiers in Oncology, 11, Article 638288. https://doi.org/10.3389/fonc.2021.638288
|
[5]
|
Choi, T., Choi, I.Y., Han, K., et al. (2021) Lipid Level, Lipid Variability, and Risk of Multiple Myeloma: A Nationwide Population-Based Study of 3,527,776 Subjects. Cancers, 13, Article 540. https://doi.org/10.3390/cancers13030540
|
[6]
|
Lim, J.S.L., Chong, P.S.Y. and Chng, W.J. (2022) Metabolic Vulnerabilities in Multiple Myeloma. Cancers, 14, Article 1905. https://doi.org/10.3390/cancers14081905
|
[7]
|
Rajkumar, S.V. (2016) Myeloma Today: Disease Definitions and Treatment Advances. American Journal of Hematology, 91, 90-100. https://doi.org/10.1002/ajh.24236
|
[8]
|
Dmoszyńska, A., Podhorecka, M., Roliński, J., et al. (2004) Influence of Lovastatin on BCL-2 and BAX Expression by Plasma Cells and T Lymphocytes in Short-Term Cultures of Multiple Myeloma Bone Marrow Mononuclear Cells. Polish Journal of Pharmacology, 56, 485-489.
|
[9]
|
Van der Spek, E., Bloem, A.C., Van de Donk, N.W., et al. (2006) Dose-Finding Study of High-Dose Simvastatin Combined with Standard Chemotherapy in Patients with Relapsed or Refractory Myeloma or Lymphoma. Haematologica, 91, 542-545.
|
[10]
|
Dai, Y., Khanna, P., Chen, S., et al. (2007) Statins Synergistically Potentiate 7-Hydroxystaurosporine (UCN-01) Lethality in Human Leukemia and Myeloma Cells by Disrupting Ras Farnesylation and Activation. Blood, 109, 4415-4423. https://doi.org/10.1182/blood-2006-09-047076
|
[11]
|
Jánosi, J., Sebestyén, A., Bocsi, J., et al. (2004) Mevastatin-Induced Apoptosis and Growth Suppression in U266 Myeloma Cells. Anticancer Research, 24, 1817-1822.
|
[12]
|
Otsuki, T., Sakaguchi, H., Hatayama, T., et al. (2004) Effects of an HMG-CoA Reductase Inhibitor, Simvastatin, on Human Myeloma Cells. Oncology Reports, 11, 1053-1058. https://doi.org/10.3892/or.11.5.1053
|
[13]
|
Schmidmaier, R., Baumann, P., Simsek, M., et al. (2004) The HMG-CoA Reductase Inhibitor Simvastatin Overcomes Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma by Geranylgeranylation of Rho Protein and Activation of Rho Kinase. Blood, 104, 1825-1832. https://doi.org/10.1182/blood-2003-12-4218
|
[14]
|
王丽, 赵艳莉, 金瑄, 等. 多发性骨髓瘤患者的血清β2-MG、TNF-α、IL-6水平及其临床意义[J]. 海南医学, 2020, 31(12): 1527-1529.
|
[15]
|
叶筱颖, 王子峰, 张娟, 等. 多发性骨髓瘤患者肺部感染病原菌分布特征及血清β2-MG、CRP对肺部感染的诊断价值[J]. 中国病原生物学杂志, 2021, 16(9): 1069-1072.
|
[16]
|
费晓莉, 章帆, 张开基, 等. IL-32, Cys-C和β2-MG在多发性骨髓瘤患者外周血中的表达[J]. 西南大学学报(自然科学版), 2021, 43(3): 30-35.
|
[17]
|
张勇军. β2-微球蛋白在肿瘤诊断和监测中的应用价值[J]. 检验医学与临床, 2013, 10(6): 699 701.
|
[18]
|
左立辉, 李四强, 秦伟, 等. 血清SCD54、Presepsin水平对多发性骨髓瘤的诊断价值及与患者预后的关系[J]. 国际检验医学杂志, 2022, 43(9): 1124-1128.
|
[19]
|
蔡宜诺, 刘景华, 王吉刚, 等. 新诊断多发性骨髓瘤肾功能亚型组间细胞遗传学及生化特点比较[J]. 现代肿瘤医学, 2022, 30(9): 1664-1667.
|
[20]
|
崔珺, 朱红青, 刘凌泉, 等. 不同剂量硼替佐米联合地塞米松对多发性骨髓瘤T细胞亚群及血清C反应蛋白、β2-微球蛋白的影响[J]. 现代生物医学进展, 2020, 20(9): 1720-1723.
|
[21]
|
Liang, L., Li, J., Fu, H., et al. (2019) Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. Journal of Cancer, 10, 4852-4859. https://doi.org/10.7150/jca.31357
|
[22]
|
Zamanian-Daryoush, M., Lindner, D., Tallant, T.C., et al. (2013) The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-Tumorigenic Effects. The Journal of Biological Chemistry, 288, 21237-21252. https://doi.org/10.1074/jbc.M113.468967
|
[23]
|
Clark, D.M. and Lampert, I.A. (1990) Apoptosis Is a Common Histopathological Finding in Myelodysplasia: The Correlate of Ineffective Haematopoiesis. Leukemia & Lymphoma, 2, 415-418. https://doi.org/10.3109/10428199009069295
|
[24]
|
Raza, A., Alvi, S., Broady-Robinson, L., et al. (1997) Cell Cycle Kinetic Studies in 68 Patients with Myelodysplastic Syndromes Following Intravenous Iodo-and/or Bromodeoxyuridine. Experimental Hematology, 25, 530-535.
|
[25]
|
Kesaniemi, Y.A., Witztum, J.L. and Steinbrecher, U.P. (1983) Receptor-Mediated Catabolism of Low Density Lipoprotein in Man. Quantitation Using Glucosylated Low Density Lipoprotein. The Journal of Clinical Investigation, 71, 950-959. https://doi.org/10.1172/JCI110849
|
[26]
|
Tirado-Vélez, J.M., Benítez-Rondán, A., Cózar-Castellano, I., et al. (2012) Low-Density Lipoprotein Cholesterol Suppresses Apoptosis in Human Multiple Myeloma Cells. Annals of Hematology, 91, 83-88. https://doi.org/10.1007/s00277-011-1246-8
|
[27]
|
Tosi, M.R. and Tugnoli, V. (2005) Cholesteryl Esters in Malignancy. Clinica Chimica Acta, International Journal of Clinical Chemistry, 359, 27-45. https://doi.org/10.1016/j.cccn.2005.04.003
|
[28]
|
Ganjali, S., Banach, M., Pirro, M., et al. (2021) HDL and Cancer—Causality Still Needs to Be Confirmed? Update 2020. Seminars in Cancer Biology, 73, 169-177. https://doi.org/10.1016/j.semcancer.2020.10.007
|
[29]
|
Yvan-Charvet, L., Pagler, T., Gautier, E.L., et al. (2010) ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation. Science, 328, 1689-1693. https://doi.org/10.1126/science.1189731
|